TRex Bio (NASDAQ:TRXB) Now Covered by JPMorgan Chase & Co.

Equities research analysts at JPMorgan Chase & Co. started coverage on shares of TRex Bio (NASDAQ:TRXB) in a report released on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $20.00 price target on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 46.63% from the company’s previous close.

Separately, Wedbush began coverage on shares of TRex Bio in a research report on Monday. They issued an “outperform” rating and a $30.00 target price on the stock. Four research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $29.67.

TRex Bio Price Performance

NASDAQ TRXB opened at $13.64 on Tuesday. TRex Bio has a twelve month low of $13.10 and a twelve month high of $16.56.

Insider Activity at TRex Bio

In other news, major shareholder Alexandria Venture Investments acquired 178,571 shares of the company’s stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the purchase, the insider owned 1,346,501 shares of the company’s stock, valued at $18,851,014. This represents a 15.29% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.